Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formation.
Costa F, Toscani D, Chillemi A, Quarona V, Bolzoni M, Marchica V, Vescovini R, Mancini C, Martella E, Campanini N, Schifano C, Bonomini S, Accardi F, Horenstein AL, Aversa F, Malavasi F, Giuliani N.
Costa F, et al.
Oncotarget. 2017 May 16;8(34):56598-56611. doi: 10.18632/oncotarget.17896. eCollection 2017 Aug 22.
Oncotarget. 2017.
PMID: 28915615
Free PMC article.